A review of the genetic and related effects of 1,3-butadiene in rodents and humans

Mutation Research - Reviews in Mutation Research

Volumn 463, Issue 3, 2000, Pages 181-213

  Jackson, Marcus A ^a   Stack, H Frank ^a   Rice, Jerry M ^b   Waters, Michael D ^c  

^a Alpha Gamma Technologies Inc   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

1,3 Butadiene; Carcinogenic risk; DNA adducts; Genetic activity; Human versus Rodent; Oxidative metabolites

Indexed keywords

1,2 EPOXY 3 BUTENE; 1,3 BUTADIENE DERIVATIVE; 3,4 EPOXY 1,2 BUTANEDIOL; BUTADIENE DIEPOXIDE; UNCLASSIFIED DRUG;

CANCER RISK; CHEMICAL CARCINOGENESIS; CHEMICAL MUTAGENESIS; DNA ADDUCT; GENE MUTATION; GENOTOXICITY; HUMAN; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; XENOBIOTIC METABOLISM;

ANIMALIA; RODENTIA;

EID: 0033795176     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(00)00056-9     Document Type: Article

References (173)

1. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 71, Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide (Part one), Lyon, 1999 pp. 109-225.
2. Chemical Week CW product focus: butadiene, Chem. Week, June 15 (1994) 56.
3. Henderson R.F. 1,3-Butadiene: introduction to the problem. HEI Commun. 6:1999;13-25.
4. Himmelstein M.W., Acquavella J.F., Recio L., Medinsky M.A., Bond J.A. Toxicology and epidemiology of 1,3-butadiene. Crit. Rev. Toxicol. 27:1997;1-108.
5. Divine B.J. An update on mortality among workers at a 1,3-butadiene facility-preliminary results. Environ. Health Perspect. 86:1990;119-128.
6. B.J. Divine, J.K. Wendt, C.M. Hartman, Cancer mortality among workers at a butadiene production facility, in: M. Sorsa, K. Peltonen, H. Vainio, K. Hemminki (Eds.), Butadiene and Styrene: Assessment of Health Hazards, IARC Scientific Publication No. 127, International Agency for Research on Cancer, Lyon, 1993, pp. 345-362.
7. Downs T.D., Crane M.M., Kim K.W. Mortality among workers at a butadiene facility. Am. J. Ind. Med. 12:1987;311-329.
8. Matanoski G.M., Schwartz L. Mortality of workers in styrene-butadiene polymer production. J. Occup. Med. 29:1987;675-680.
9. Matanoski G.M., Santos-Burgoa C., Schwartz L. Mortality of a cohort of workers in the styrene-butadiene polymer manufacturing industry (1943-1982). Environ. Health Perspect. 86:1990;107-117.
10. Meinhardt T.J., Lemen R.A., Crandall M.S., Young R.J. Environmental epidemiologic investigation of the styrene-butadiene rubber industry. Mortality patterns with discussion of hematopoietic and lymphatic malignancies. Scand. J. Work Environ. Health. 8:1982;250-259.
11. Santos-Burgoa C., Matanoski G.M., Zeger S., Schwartz L. Lymphohematopoietic cancer in styrene-butadiene polymerization workers. Am. J. Epidemiol. 136:1992;843-854.
12. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 54, Occupational Exposures to Mists and Vapours from Strong Inorganic Acids and Other Industrial Chemicals, Lyon, 1992, pp. 237-285.
13. Delzell E., Sathiakumar N., Hovinga M., Macaluso M., Julian J., Larson R., Cole P., Muir D.C. A follow-up study of synthetic rubber workers. Toxicology. 113:1996;182-189.
14. Macaluso M., Larson R., Delzell E., Sathiakumar N., Hovinga M., Julian J., Muir D., Cole P. Leukemia and cumulative exposure to butadiene styrene and benzene, among workers in the synthetic rubber industry. Toxicology. 113:1996;190-202.
15. Divine B.J., Hartman C.M. Mortality update of butadiene production workers. Toxicology. 113:1996;169-181.
16. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J. Lymphoma classification-from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 11(Suppl. 1):2000;3-10.
17. The World Health Organization, The International Classification for Disease for Oncology, 3rd Edition, in press.
18. Melnick R.L., Huff J., Chou B.J., Miller R.A. Carcinogenicity of 1,3-butadiene in C57BL/6×C3HF1 mice at low exposure concentrations. Cancer Res. 50:1990;6592-6599.
19. US National Toxicology Program, Toxicology and carcinogenesis studies of 1,3-butadiene (CAS No 106-99-0) in B6C3F1 mice (inhalation studies), TR 288 NIH 84-2544, NTP, Research Triangle Park, NC, 1984.
20. US National Toxicology Program, Toxicology and carcinogenesis studies of 1,3-butadiene (CAS No 106-99-0) in B6C3F1 mice (inhalation studies) TR 434 NIH 93-3165, NTP, Research Triangle Park, NC, 1993.
21. Owen P.E., Glaister J.R., Gaunt I.F., Pullinger D.H. Inhalation toxicity studies with 1,3-butadiene. 3. Two year toxicity/carcinogenicity study in rats. J. Am. Ind. Hyg. Assoc. 48:1987;407-413.
22. Owen P.E., Glaister J.R. Inhalation toxicity and carcinogenicity of 1,3-butadiene in Sprague-Dawley rats. Environ. Health Perspect. 86:1990;19-25.
23. Waters M.D., Stack H.F., Brady A.L., Lohman P.H.M., Haroun L., Vainio H. Use of computerized data listings and activity profiles of genetic and related effects in the review of 195 compounds. Mutat. Res. 205:1988;295-312.
24. Bolt H.M., Schmiedel G., Filser J.G., Rolzhauser H.P., Lieser K., Wistuba D., Schurig V. Biological activation of 1,3-butadiene to vinyl oxirane by rat liver microsomes and expiration of the reactive metabolite by exposed rats. Cancer Res. Clin. Oncol. 106:1983;112-216.
25. Csanady G.A., Guengerich F.P., Bond J.A. Comparison of the biotrasformation of 1,3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. Carcinogenesis. 13:1992;1143-1153.
26. Deuscher R.J., Elfarra A.A. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence of major roles by cytochrome P450 2A6 and 2E1. Arch. Biochem. Biophys. 311:1994;342-349.
27. Himmelstein M.W., Turner M.J., Asgharian B., Bond J.A. Comparison of blood concentrations of 1,3-butadiene and butadiene epoxides in mice and rats exposed to 1,3-butadiene. Carcinogenesis. 15:1994;1479-1486.
28. Himmelstein M.W., Asgharian B., Bond J.A. High concentrations of butadiene epoxides in livers and lungs of mice compared to rats exposed to 1,3-butadiene. Toxicol. Appl. Pharmacol. 132:1995;281-288.
29. Malvoisin E., Lhoest G., Poncelet F., Roberfroid M., Mercier M. Identification and quantitation of 1,2-epoxybutene-3 as the primary metabolite of 1,3-butadiene. J. Chromatogr. 178:1979;419-425.
30. Schmidt U., Loeser E. Species differences in the formation of butadiene monoxide from 1,3-butadiene. Arch. Toxicol. 57:1982;222-225.
31. Thornton-Manning J.R., Dahl A.R., Bechtold W.E., Griffith W.C. Jr., Henderson R.F. Disposition of butadiene monoepoxide and butadiene diepoxide in various tissues of rats and mice following a low-level inhalation exposure to 1,3-butadiene. Carcinogenesis. 16:1995a;1723-1731.
32. Thornton-Manning J.R., Dahl A.R., Bechtold W.E., Griffith W.C., Pei L., Henderson R.F. Gender differences in the metabolism of 1,3-butadiene in Sprague Dawley rats following a low-level inhalation exposure. Carcinogenesis. 16:1995b;2875-2878.
33. Boogaard P.J., Bond J.A. The role of hydrolysis in the detoxification of 1,2:3,4-diepoxybutane by human, rat, and mouse liver and lung in vitro. Toxicol. Appl. Pharamcol. 141:1996;617-627.
34. Cheng X., Ruth R.A. A simplified methodology for quantitation of butadiene metabolites: application to the study of 1,3-butadiene metabolism by rat liver microsomes. Drug Metab. Dispos. 21:1993;121-124.
35. Malvoisin E., Roberfroid M. Hepatic microsomal metabolism of 1,3-butadiene. Xenobiotica. 12:1982;137-144.
36. ECETOC Special Report No. 12, 1,3-Butadiene OEL Criteria Document, 2nd Edition, Cas. No. 106-99-0 (1997), pp. 1-57.
37. Seaton M.J., Follansbee M.H., Bond J.A. Oxidation of 1,2-epoxy-3-butene by cDNA-expressed human cytochromes P450 2E1 and 3A4 and human, mouse, and rat liver microsomes. Carcinogenesis. 18:1995;2287-2292.
38. Nauhaus S.K., Fennel T.R., Asgharian B., Bond J.A., Summer S.C.J. Characterization of urinary metabolites from Sprague-Dawley rats and B6C3F1 mice exposed to [1,2,3,4-13C]-butadiene. Chem. Res. Toxicol. 9:1996;7764-7773.
39. Richardson K.A., Peters M.M.C.G., Wong B.A., Megens R.H.J.J.J., van Elburg P.A., Booth E.D., Boogaard P.J., Bond J.A., Medinsky M.A., Watson W.P., van Sittert N.J. Quantitative and qualitative differences in the metabolism of 14C-1,3-butadiene in rats and mice: relevance to cancer susceptibility. Toxicol. Sci. 49:1999;186-201.
40. Bechtold W.E., Strunk M.R., Chang I.-Y., Ward J.B., Henderson R.F. Species differences in urinary butadiene metabolites: comparisons of metabolite ratios between mice, rats and humans. Toxicol. Appl. Pharmacol. 127:1994;44-49.
41. Hallberg L.M., Bechtold W.E., Grady J., Legator M.S., Au W.W. Abnormal DNA repair activities in lymphocytes of workers exposed to 1,3-butadiene. Mutat. Res. 383:1997;213-221.
42. R.J. Albertini, R.J. Sram, Biomarker responses in butadiene exposed Czech workers: a transitional epidemiological study, Health Effects Institute Research Report No. 92: 1,3-Butadiene and its metabolites: Interspecies comparison of carcinogenicity, mutagenicity, and biomarkers, in press.
43. R.F. Henderson, J.R. Krone, M.G. Menache, Butadiene metabolites in the urine of workers in Czechoslovokia. In: The Fourteenth Health Effects Institute Annual Conference Program and Abstracts, April 5-7, 1998, Boston, MA, Health Effects Institute, Cambridge, MA.
44. R.H.J.J.J. Megens, K.A. Evans, W.J.L. Genuit, N.J. van Sittert, Urinary metabolites M1 and M2 and hydroxybutenylvaline adducts of hemoglobin as biomarkers of butadiene exposure. In: The Fourteenth Health Effects Institute Annual Conference Program and Abstracts, April 5-7, 1998, Boston, MA, Health Effects Institute, Cambridge, MA.
45. Thornton-Manning J.R., Dahl A.R., Bechtold W.E., Griffith W.C. Jr., Henderson R.F. Comparison of the disposition of butadiene epoxides in Sprague-Dawley rats and B6C3F1 mice following a single and repeated exposures to 1,3-butadiene via inhalation. Toxicology. 123:1997;125-134.
46. Koc H., Tretyakova N.Y., Walker V.E., Henderson R.F., Swenberg J.A. Molecular dosimetry of N-7 guanine adduct formation in mice and rats exposed to 1,3-butadiene. Chem. Res. Toxicol. 12:1999;566-574.
47. Richardson K.A., Peters M.M.C.G., Megens R.H., van Elburg P.A., Golding B.T., Boogaard P.J., Watson W.P., van Sittert N.J. Identification of novel metabolites of butadiene monoepoxide in rats and mice. Chem. Res. Toxicol. 11:1998;1543-1555.
48. Thornton-Manning J.R., Dahl A.R., Allen M.L., Bechtold W.E., Griffith W.C. Jr., Henderson R.F. Disposition of butadiene epoxides in Sprague-Dawley rats following exposures to 8000 ppm 1,3-butadiene: comparison with tissue epoxide concentrations following low-level exposures. Toxicol. Sci. 41:1998;167-173.
49. Perez H.L., Lahdetie J., Landin H.H., Kilpelainen I., Koivisto P., Peltonen K., Osterman-Golkar S.M. Hemoglobin adducts of epoxybutanediol from exposure to 1,3-butadiene or butadiene epoxides. Chem. Biol. Interact. 105:1997;181-198.
50. Hayes R.B., Zhang L., Yin S., Swenberg J.A., Xi L., Wiencke J., Bechtold W.E., Yao M., Rothman N., Haas R., O'Neill J.P., Zhang D., Wiemels J., Dosemeci M., Li G., Smith M.T. Genotoxic markers among butadiene polymer workers in China. Carcinogenesis. 21:2000;55-62.
51. J.A. Swenberg, P.B. Upton, A. Ranasinghe, R. Albertini, R.J. Sram, Hemoglobin adducts as biomarkers of butadiene exposure in workers from the Czech Republic. In: The Fourteenth Health Effects Institute Annual Conference Program and Abstracts, April 5-7, 1998, Boston, MA, Health Effects Institute, Cambridge, MA.
52. Boogaard P.J., Sumner S.C-J., Bond J.A. Glutathione conjugation of 1,2:3,4-diepoxybutane in human liver and rat and mouse liver and lung in vitro. Toxicol. Appl. Pharamcol. 136:1996;307-316.
53. Filser J.G., Altthaler B., Welter H.F., Johanson G. Metabolism of 1,3-butadiene in microsomes from livers of mouse, rat (Abstract No. 124). Naunyn-Schmiedeberg's Arch. Pharmacol. Suppl. 345:1992;R31.
54. Kreuzer P.E., Kessler W., Welter H.F., Baur C., Filser J.G. Enzyme specific kinetics of 1,2-epoxybutene-3 in microsomes and cytosol from livers of mouse, rat, and man. Arch. Toxicol. 65:1991;59-67.
55. Bond J.A., Csanady G.A., Gargas M.L., Guengerich F.P., Leavens T., Medinsky M.A., Recio L. 1,3-Butadiene: linking metabolism, dosimetry, and mutation induction. Environ. Health Perspect. 109(Suppl. 9):1994;87-94.
56. Csanady G.A., Kreuzer P.E., Baur C., Filser J.G. A physiologic toxicokinetic model for 1,3-butadiene in rodents and man: blood concentrations of 1,3-butadiene, its metabolically formed epoxides, and of hemoglobin adducts-relevance of glutathione depletion. Toxicology. 113:1996;300-305.
57. Evelo C.T.A., Oostendorp J.G.M., Ten Berge W.F., Borm P.J.A. Physiologically based toxicokinetic modeling of 1,3-butadiene lung metabolism in mice becomes more important at low doses. Environ. Health Perspect. 101:1993;496-502.
58. J.G. Filser, G. Johanson, W. Kessler, P.E. Kreuzer, P. Stei, C. Baur, G.A. Csanady, A pharmacokinetic model to describe toxicokinetic interactions between 1,3-butadiene and styrene in rats: predictions for human exposure, in: M. Sorsa, K. Peltonen, H. Vainio, K. Hemminki (Eds.), Butadiene and Styrene: Assessment of Health Hazards, IARC Scientific Publications No. 127, International Agency for Research on Cancer, Lyon, 1993, pp. 65-78.
59. Johanson G., Filser J.G. A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation. Arch. Toxicol. 67:1993;151-163.
60. Kohn M.C., Melnick R.L. Species differences in the production and clearance of 1,3-butadiene metabolites: a mechanistic model indicates predominantly physiological not biochemical control. Carcinogenesis. 14:1993;619-628.
61. Medinsky M.A., Leavens T.L., Csanady G.A., Gargas M.L., Bond J.A. In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data. Carcinogenesis. 15:1994;1329-1340.
62. Sweeney L.M., Schlosser P.M., Medinsky M.A., Bond J.A. Physiologically based pharmacokinetic modeling of 1,3-butadiene, 1,2-epoxy-3-butene, and 1,2:3,4-diepoxybutane toxicokinetics in mice and rats. Carcinogenesis. 18:1997;611-625.
63. Osterman-Golkar S.M., Peltonen K., Aniottinen-Klemetti T., Landin H.H., Zorcec V., Sorsa M. Hemoglobin adducts as biomarkers of occupational exposure to 1,3-butadiene. Mutagenesis. 11:1996;145-149.
64. Osterman-Golkar S.M., Moss O., James A., Bryant M.S., Turner M., Bond J.A. Epoxybutene-hemoglobin adducts in rats and mice: dose response for formation and persistence during and following long-term low-level exposure to butadiene. Toxicol. Appl. Pharmacol. 150:1998;166-173.
65. Carmical J.R., Zhang M., Nechev L., Harris C.M., Harris T.M., Lloyd R.S. Mutagenic porential of guanine N2 adducts of butadiene mono-and diolepoxide. Chem. Res. Toxicol. 13:2000;18-25.
66. Koivisto P., Kilpelainen I., Rasanen I., Adler I.-D., Pacchierotti F., Peltonen K. Butadiene diolepoxide- and diepoxybutane-derived DNA adducts at N7-guanine: a high occurrence of diolepoxide-derived adducts in mouse lung after 1,3-butadiene exposure. Carcinogenesis. 20:1999;1253-1259.
67. Oe T., Kambouris S.J., Walker V.E., Meng Q., Recio L., Wherli S., Chaudhary A.K., Blair I.A. Persistence of N7-(2,3,4-trihydroxybutyl)guanine adducts in the livers of mice and rats exposed to 1,3-butadiene. Chem. Res. Toxicol. 12:1999;247-257.
68. Zhao C., Vodicka P., Sram R.J., Hemminki K. Human DNA adducts of 1,3-butadiene an important environmental carcinogen. Carcinogenesis. 21:2000;107-111.
69. Koivisto P., Adler I.-D., Pacchierotti F., Peltonen K. DNA adducts in mouse testis and lung after inhalation exposure to 1,3-butadiene. Mutat. Res. 397:1998;3-10.
70. Lombard L.S., Rice J.M., Vesselinovitch S.D. Renal tumors in mice: light microscopic observations of epithelial tumors induced by ethylnitrosourea. J. Natl. Cancer Inst. 53:1974;1677-1685.
71. C.H. Frith, B. Terracini, V.S. Turusov, Tumors of the kidney, renal pelvis and ureter, in: V. Turusov, U. Mohr (Eds.), Pathology of Tumours in Laboratory Animals, Vol. 2, Tumours of the Mouse, 2nd Edition, IARC Scientific Publications No. 111, International Agency for Research on Cancer, Lyon, 1994, pp. 357-381.
72. Koivisto P., Adler I.-D., Sorsa M., Peltonen K. Inhalation exposure of rats and mice to 1,3-butadiene induces N6-adenine adducts of epoxybutene detected by 32P-postlabeling and HPLC. Environ. Health Perspect. 104:1996;655-657.
73. Bolt H.M., Jelitto B. Biological formation of the 1,3-butadiene DNA adducts 7-N-(2-hydroxy-3-buten-1-yl)guanine, 7-N-(1-hydroxy-3-buten-2-yl)guanine and 7-N-(2,3,4-trihydroxy-butyl)guanine. Toxicology. 113:1996;328-330.
74. Jelitto B., Vangala R.R., Laib R.J. Species differences in DNA damage by butadiene: role of diepoxybutane. Arch. Toxicol. Suppl. 13:1989;246-249.
75. Kreiling R., Laib R.J., Bolt H.M. Alkylation of nuclear proteins and DNA after exposure of rats and mice to [1,4-14C] 1,3-butadiene. Toxicol. Lett. 30:1986;131-136.
76. Zhao C., Koskinen M., Hemminki K. 32P-postlabelling of N6-adenine adducts of epoxybutanediol in vivo after 1,3-butadiene exposure. Toxicol. Lett. 102-103:1998;591-594.
77. Koivisto P., Sorsa M., Pacchierotti F., Peltonen K. 32P-Postlabeling/HPLC assay reveals an enantioselective adduct formation in N7 guanine residues in vivo after 1,3-butadiene inhalation exposure. Carcinogenesis. 18:1997;439-443.
78. Meng Q., Henderson R.F., Chen T., Heflich R.H., Walker D.M., Bauer M.J., Reilly A.A., Walker V.E. Mutagenicity of 1,3-butadiene at the Hprt locus of T-lymphocytes following inhalation exposures of female mice and rats. Mutat. Res. 429:1999a;107-125.
79. Meng Q., Recio L., Reilly A.A., Wong B.A., Bauer M., Walker V.E. Comparison of the mutagenic potency of 1,3-butadiene at the Hprt locus of T-lymphocytes following inhalation exposure of female B6C3F1 mice and F344 rats. Carcinogenesis. 19:1998;1019-1027.
80. Tates A.D., van Dam F.J., van Teylingen C.M.M., de Zwart F.A., Zwinderman A.H. Comparison of induction of Hprt mutations by 1,3-butadiene and/or its metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane in lymphocytes from spleen of adult male mice and rats in vivo. Mutat. Res. 397:1998;21-36.
81. Tates A.D., van Dam F.J., de Zwart F.A., van Teylingen C.M.M., Natarajan A.T. Development of a cloning assay with high cloning efficiency to detect induction of 6-thioguanine-resistant lymphocytes in spleen of adult mice following in vivo inhalation exposure to 1,3-butadiene. Mutat. Res. 309:1994;299-306.
82. J.E. Cochrane, T.R. Skopek, Mutagenicity of 1,3-butadiene and its epoxide metabolites in human TK6 cells and in splenic T cells isolated from exposed B6C3F1 mice, in: M. Sorsa, K. Peltonen, H. Vainio, K. Hemminki (Eds.), Butadiene and Styrene: Assessment of Health Hazards, IARC Scientific Publication No. 127, International Agency for Research on Cancer, Lyon, 1993, pp. 195-204.
83. Adler I.-D., Cao J., Filser J.G., Gassner P., Kessler W., Kliesch U., Neuhauser-Klaus A., Nusse M. Mutagenicity of 1,3-butadiene inhalation in somatic and germinal cells of mice. Mutat. Res. 309:1994;307-314.
84. A.D. Tates, F.A. de Zwart, R.J. Sram, R.J. Albertini, Use of a clonal assay to detect mutations of the HPRT gene in T-lymphocytes of workers in a butadiene monomer production facility and a butadiene polymerization plant in the Czech Republic. In: The Fourteenth Health Effects Institute Annual Conference Program and Abstracts, April 5-7, 1998, Boston, MA, Health Effects Institute, Cambridge, MA.
85. J.B. Ward, Jr., M.M. Ammenheuser, D.A. Hastings Smith, P.J. Carter, D. Rodriguez, L.M. Sullivan, Assessment of occupational exposure to 1,3-butadiene using the autoradiographic HPRT mutant lymphocyte assay. In: The Fourteenth Health Effects Institute Annual Conference Program and Abstracts, April 5-7, 1998, Boston, MA, Health Effects Institute, Cambridge, MA.
86. Hayes R.B., Xi L., Bechtold W.E., Rothman N., Yao M., Henderson R., Zhang L., Smith M.T., Zhang D., Wiemels J., Dosemeci M., Yin S., O'Neill J.P. Hprt Mutation frequency among workers exposed to 1,3-butadiene in China. Toxicology. 113:1996;100-105.
87. Tates A.D., van Dam F.J., de Zwart F.A., Darroudi F., Natarajan A.T., Rossner P., Peterkova K., Peltonen K., Demopoulos N.A., Stephanou G., Vlachodimitropoulos D., Sram R.J. Biological effect monitoring in industrial workers from the Czech Republic exposed to low levels of butadiene. Toxicology. 113:1996;91-99.
88. Ward J.B. Jr., Ammenheuser M.M., Whorton E.B. Jr., Bechtold W.E., Kelsey K.T., Legator M.S. Biological monitoring for mutagenic effects of occupational exposure to butadiene. Toxicology. 113:1996;84-90.
89. Ward J.B. Jr., Ammenheuser M.M., Bechtold W.E., Whorton E.B. Jr., Legator M.S. HPRT Mutant lymphocyte frequencies in workers at a 1,3-butadiene production plant. Environ. Health Perspect. 102(Suppl. 9):1994;79-85.
90. Tice R.R., Boucher R., Luke C.A., Shelby M.D. Comparative cytogenetic analysis of bone marrow damage induced in male B6C3F1 mice by multiple exposures to gaseous 1,3-butadiene. Environ. Mutagen. 9:1987;235-250.
91. Cunningham M.J., Choy W.N., Arce G.T., Rickard L.B., Vlachos D.A., Kinney L.A., Sarrif A.M. In vivo sister chromatid exchange and micronucleus induction studies with 1,3-butadiene in B6C3F1 mice and Sprague-Dawley rats. Mutagenesis. 1:1986;449-452.
92. R.J. Sram, P. Rossner, J. Rubes, P. Musilova, B. Binkova, P. Vacek, R.J. Albertini, Biomarkers responses in butadiene exposed Czech workers. II. Cytogenetic analysis. In: The Fourteenth Health Effects Institute Annual Conference Program and Abstracts, April 5-7, 1998, Boston, MA, Health Effects Institute, Cambridge, MA.
93. Sram R.J., Rossner P., Peltonen K., Podrazilova K., Mrackova G., Demopoulos N.A., Stephanou G., Vlachodimitropoulos D., Darroudi F., Tates A.D. Chromosomal aberrations, sister-chromatid exchanges, cells with high frequency of SCE, micronuclei and comet assay parameters in 1,3-butadiene-exposed workers. Mutat. Res. 419:1998;145-154.
94. Kelsey K.T., Wiencke J.K., Ward J., Bechtold W., Fajen J. Sister-chromatid exchanges, glutathione S-transferase theta deletion and cytogenetic sensitivity to diepoxybutane in lymphocytes from butadiene monomer production workers. Mutat. Res. 335:1995;267-273.
95. Sorsa M., Autio K., Demopoulos N.A., Jarventaus H., Rossner P., Sram R.J., Stephanou G., Vlachodimitropoulos D. Human cytogenetic biomonitoring of occupational exposure to 1,3-butadiene. Mutat. Res. 309:1994;321-326.
96. Autio K., Renzi L., Catalan J., Albrecht O.E., Sorsa M. Induction of micronuclei in peripheral blood and bone marrow erythrocytes of rats and mice exposed to 1,3-butadiene by inhalation. Mutat. Res. 309:1994;315-320.
97. Victorin K., Busk L., Cederberg H., Magnusson J. Genotoxic activity of 1,3-butadiene and nitrogen dioxide and their photochemical reaction products in Drosophila and in mouse bone marrow micronucleus assay. Mutat. Res. 228:1990;203-209.
98. Jauhar P.P., Henika P.R., MacGregor J.T., Wehr C.M., Shelby M.D., Murphy S.A., Margolin B.H. 1,3-Butadiene: Induction of micronucleated erythrocytes in the peripheral blood of B6C3F1 mice exposed by inhalation for 13 weeks. Mutat. Res. 209:1988;171-176.
99. Stephanou G., Russo A., Vlastos D., Andrianopoulos C., Demopoulos N.A. Micronucleus induction in somatic cells of mice as evaluated after 1,3-butadiene inhalation. Mutat. Res. 397:1998;11-20.
100. Tommasi A.M., de Conti S., Dobrzynska M.M., Russo A. Evaluation and characterization of micronuclei in early spermatids of mice exposed to 1,3-butadiene. Mutat. Res. 397:1998;45-54.
101. Xiao Y., Tates A.D. Clastogenic effects of 1,3-butadiene and its metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane in splenocytes and germ cells of rats and mice in vivo. Environ. Health Perspect. 26:1995;97-108.
102. Irons R.D., Oshimura M., Barrett J.C. Chromosome aberrations in mouse bone marrow cells following in vivo exposure to 1,3-butadiene. Carcinogenesis. 8:1987;1711-1714.
103. Pacchierotti F., Tiveron C., Ranaldi R., Bassani B., Cordelli E., Leter G., Spano M. Reproductive toxicity of 1,3-butadiene in the mouse: cytogenetic analysis of chromosome aberrations in first-cleavage embryos and flow cytometric evaluation of spermatogonial cell killing. Mutat. Res. 397:1998a;55-66.
104. Adler I.-D., Filser J., Gonda H., Schriever-Schwemmer G. Dose response study of 1,3-butadiene-induced dominant lethal mutations and heritable translocations in germ cells of male mice. Mutat. Res. 397:1998;85-92.
105. Anderson D., Hughes J.A., Edwards A.J., Brinkworth M.H. A comparison of male-mediated effects in rats and mice exposed to 1,3-butadiene. Mutat. Res. 397:1998;77-84.
106. Brinkworth M.H., Anderson D., Hughes J.A., Jackson L.I., Yu T.-W., Nieschlag E. Genetic effects of 1,3-butadiene on the mouse testis. Mutat. Res. 397:1998;67-75.
107. D. Anderson, A.J. Edwards, M.H. Brinkworth. Male-mediated F1 effects in mice exposed to 1,3-butadiene, in: M. Sorsa, K. Peltonen, H. Vainio, K. Hemminki (Eds.), Butadiene and Styrene: Assessment of Health Hazards, IARC Scientific Publication No. 127, International Agency for Research on Cancer, Lyon, 1993, pp. 171-181.
108. Morrissey R.E., Schwetz B.A., Hackett P.L., Sikov M.R., Hardin B.D., McClanahan B.J., Decker J.R., Mast T.J. Overview of reproductive and developmental toxicity studies of 1,3-butadiene in rodents. Environ. Health Perspect. 86:1990;79-84.
109. Adler I.-D., Filser J.G., Gassner P., Kessler W., Schoneich J., Schriever-Schwemmer G. Heritable translocations induced by inhalation exposure of male mice to 1,3-butadiene. Mutat. Res. 347:1995a;121-127.
110. M.S. Legator, W.W. Au, M. Ammenheuser, J.B. Ward, Jr., Elevated somatic cell mutant frequencies and altered DNA repair responses in nonsmoking workers exposed to 1,3-butadiene. in: M. Sorsa, K. Peltonen, H. Vainio, K. Hemminki (Eds.), IARC Scientific Publications No. 127, Butadiene and Styrene: Assessment of Health Hazards, International Agency for Research on Cancer, Lyon, 1993, pp. 253-263.
111. Vangala R.R., Laib R.J., Bolt H.M. Evaluation of DNA damage by alkaline elution technique after inhalation exposure of rats and mice to 1,3-butadiene. Arch. Toxicol. 67:1993;34-38.
112. Ristau C., Deutschmann S., Laib R.J., Ottenwalder H. Detection of diepoxybutane-induced DNA-DNA cross-links by cesium trifluoracetate (CsTFA) density-gradient centrifugation. Arch. Toxicol. 64:1990;343-344.
113. Walles S.A.S., Victorin K., Lundborg M. DNA damage in lung cells in vivo and in vitro by 1,3-butadiene and nitrogen dioxide and their photochemical reaction products. Mutat. Res. 328:1995;11-19.
114. Meng Q., Singh N., Heflich R.H., Bauer M.J., Walker V.E. Comparison of the mutations at Hprt exon 3 of T-lymphocytes from B6C3F1 mice and F344 rats exposed by inhalation to 1,3-butadiene or the racemic mixture of 1,2:3,4-diepoxybutane. Mutat. Res. 464:2000;169-184.
115. Recio L., Meyer K.G. Increased frequency of mutations at A:T base pairs in the bone marrow of B6C3F1 lacI transgenic mice exposed to 1,3-butadiene. Environ. Mol. Mutagen. 26:1995;1-8.
116. L. Recio, L.J. Pluta, K.G. Meyer, The in vivo mutagenicity and mutational spectrum at the lacI transgene recovered from the spleens of B6C3F1 lacI transgenic mice following a 4-week inhalation exposure to 1,3-butadiene, Mutat. Res. (1998) 99-110.
117. Recio L., Osterman-Golkar S., Csanady G.A., Turner M.J., Myhr B., Moss O., Bond J.A. Determination of mutagenicity in tissues of transgenic mice following exposure to 1,3-butadiene and N-ethyl-N-nitrosourea. Toxicol. Appl. Pharmacol. 117:1992;58-64.
118. Zhuang S.-M., Cochran C., Goodrow T., Wiseman R.W., Soderkvist P. Genetic alterations of p53 and ras genes in 1,3-butadiene- and 2′,3′-dideoxycytidine-induced lymphomas. Cancer Res. 57:1997;2710-2714.
119. Williams J.R., Russell J., Dicello J.F., Mabry M.H. The genotype of the human cancer cell: implications for risk analysis. Mutat. Res. 365:1996;17-42.
120. Knudson A.G. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U. S. A. 90:1993;10914-10921.
121. C.J. Conti, I.B. Gimenez-Conti, Molecular genetic alterations as intermediate endpoints in chemoprevention studies, in: B.W. Stewart, D. McGregor, P. Kleihues (Eds.), Principles of Chemoprevention, IARC Scientific Publication No. 139, International Agency for Research on Cancer, Lyon, 1996, pp. 249-260.
122. Goodrow T., Reynolds S., Maronpot R., Anderson M. Activation of K-ras by codon 13 mutations in C57BL/6×C3HF1 mouse tumors induced by exposure to 1,3-butadiene. Cancer Res. 50:1990;4818-4823.
123. Jacobson-Kram D., Rosenthal S.L. Molecular and genetic toxicology of 1,3-butadiene. Mutat. Res. 339:1995;121-130.
124. Goodrow T.L., Nichols W.W., Storer R.D., Anderson M.W., Maronpot R.R. Activation of H-ras is prevalent in 1,3-butadiene-induced and spontaneously occurring murine Harderian gland tumors. Carcinogenesis. 15:1994;2665-2667.
125. J.L. Bos, C.F. van Kreijl, Genes and gene products that regulate proliferation and differentiation: critical targets in carcinogenesis, in: H. Vainio, P.N. Magee, D.B. McGregor, A.J. McMichael (Eds.), Mechanisms of Carcinogenesis in Risk Identification, IARC Scientific Publication No. 116, International Agency for Research on Cancer, Lyon, 1992, pp. 57-65.
126. Byrne J.L., Marshall C.J. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br. J. Haematol. 100:1998;256-264.
127. Anderson D., Hughes J.A., Brinkworth M.H., Peltonen K., Sorsa M. Levels of ras oncoproteins in human plasma from 1,3-butadiene-exposed workers and controls. Mutat. Res. 349:1996;115-120.
128. Sorsa M., Osterman-Golkar S., Peltonen K., Saarikoski S.T., Sram R. Assessment of exposure to butadiene in the process industry. Toxicology. 113:1996;77-83.
129. Meng Q., Henderson R.F., Chen T., Walker D.M., Bauer M.J., Reilly A.A., Walker V.E. Mutagenicity of the racemic mixtures of butadiene monoepoxide and butadiene diepoxide at the Hprt locus of T-lymphocytes following inhalation exposures of female mice and rats. Mutat. Res. 429:1999b;127-140.
130. Cochrane J.E., Skopek T.R. Mutagenicity of butadiene and its epoxide metabolites: II. Mutational spectra of butadiene 1,2-epoxybutene and diepoxybutane at the Hprt locus in splenic T cells from exposed B6C3F1 mice. Carcinogenesis. 15:1994;719-723.
131. Steen A.M., Meyer K.G., Recio L. Characterization of HPRT mutations following 1,2-epoxy-3-butene exposure of human TK6 cells. Mutagenesis. 12:1997a;359-364.
132. Sharief Y., Brown A.M., Backer L.C., Campbell J.A., Westbrook-Collins B., Stead A.G., Allen J.W. Sister chromatid exchange and chromosome aberration analyses in mice after in vivo exposure to acrylonitrile, styrene, or butadiene monoxide. Environ. Mutagen. 8:1986;439-448.
133. Kligerman A.D., DeMarini D.M., Doerr C.L., Hanley N.M., Milholland V.S., Tennant A.H. Comparison of cytogenetic effects of 3,4-epoxy-1-butene and 1,2:3,4-diepoxybutane in mouse rat and human lymphocytes following in vitro Go exposures. Mutat. Res. 439:1999;13-23.
134. Bernardini S., Hirvonen A., Pelin K., Norppa H. Induction of sister chromatid exchange by 1,2-epoxy-3-butene in cultured human lymphocytes: influence of GSTT1 genotype. Carcinogenesis. 19:1998;377-380.
135. Bernardini S., Pelin K., Peltonen K., Jarventaus H., Hirvonen A., Neagu C., Sorsa M., Norppa H. Induction of sister chromatid exchange by 3,4-epoxybutene-1,2-diol in cultured human lymphocytes of different GSTT1 and GSTM1genotypes. Mutat. Res. 361:1996;121-127.
136. Uuskula M., Jarventaus H., Hirvonen A., Sorsa M., Norppa H. Influence of GSTM1 genotype on sister chromatid exchange induction by styrene-7,8-oxide and 1,2-epoxy-3-butene in cultured human lymphocytes. Carcinogenesis. 16:1995;947-950.
137. J.K. Wiencke, K.T. Kelsey, Susceptibility to induction of chromosomal damage by metabolites of 1,3-butadiene and its relationship to spontaneous sister chromatid exchange frequencies in human lymphocytes, in: M. Sorsa, K. Peltonen, H. Vainio, K. Hemminki (Eds.), Butadiene and Styrene: Assessment of Health Hazards, IARC Scientific Publication No. 127, International Agency for Research on Cancer, Lyon, 1993, pp. 265-273.
138. Sasiadek M., Norppa H., Sorsa M. 1,3-Butadiene and its epoxides induce sister-chromatid exchanges in human lymphocytes in vitro. Mutat. Res. 261:1991;117-121.
139. Anderson D., Dobrzynka M.M., Jackson L.I., Yu T.-W., Brinkworth M.H. Somatic and germ cell effects in rats and mice after treatment with 1,3-butadiene and its metabolites, 1,2-epoxybutene and 1,2,3,4-diepoxybutane. Mutat. Res. 391:1997;233-242.
140. Adler I.-D., Kliesch U., Nylund L., Peltonen K. In vitro and in vivo mutagenicity of the butadiene metabolites butadiene diolepoxide, butadiene monoepoxide and diepoxybutane. Mutagenesis. 12:1997;339-345.
141. Russo A., Nogara C., Renzi L., Tommasi A.M. Micronucleus induction in germ and somatic cells of the mouse after exposure to the butadiene metabolites diepoxybutane and epoxybutene. Mutat. Res. 390:1997;129-139.
142. Lahdetie J., Grawe J. Flow cytometric analysis of micronucleus induction in rat bone marrow polychromatic erythrocytes by 1,2;3,4-diepoxybutane, 3,4-epoxy-1-butene, and 1,2-epoxybutane-3,4-diol. Cytometry. 28:1997;228-235.
143. Lahdetie J., Peltonen K., Sjoblom T. Germ cell mutagenicity of three metabolites of 1,3-butadiene in the rat: induction of spermatid micronuclei by butadiene mono-, di-, and diolepoxides in vivo. Environ. Mol. Mutagen. 29:1997;230-239.
144. Xi L., Zhang L., Wang Y., Smith M.T. Induction of chromosome-specific aneuploidy and micronuclei in human lymphocytes by metabolites of 1,3-butadiene. Carcinogenesis. 18:1997;1687-1693.
145. Vock E.H., Lutz W.K., Ilinskaya O., Vanvakas S. Discrimination between genotoxicity and cytotoxicity for the induction of DNA double-strand breaks in cells treated with aldehydes and diepoxides. Mutat. Res. 441:1999;85-93.
146. Mabon N., Randerath K. 32P-Postlabeling of 1,3-butadiene and 4-vinyl-1-cyclohexene metabolite-DNA adducts: in vitro and in vivo applications. Toxicology. 113:1996;341-344.
147. Mabon N., Moorthy B., Randerath E., Randerath K. Monophosphate
148. Steen A.-M., Meyer K.G., Recio L. Analysis of HPRT mutations occurring in human TK6 lymphoblastoid cells following exposure to 1,2,3,4-diepoxybutane. Mutagenesis. 12:1997b;61-67.
149. Walk R.A., Jenderny J., Rohrborn G., Hackenberg U. Chromosomal abnormalities and sister-chromatid exchange in bone marrow cells of mice and Chinese hamsters after inhalation and intraperitoneal administration: I. Diepoxybutane. Mutat. Res. 182:1987;333-342.
150. Conner M.K., Luo J.E., de Gotera O.G. Induction and rapid repair of sister-chromatid exchanges in multiple murine tissues in vivo by diepoxybutane. Mutat. Res. 108:1983;251-263.
151. Pelin K., Hirvonen A., Norppa H. Influence of erythrocyte glutathione S-transferase T1 on sister chromatid exchanges induced by diepoxybutane in cultured human lymphocytes. Mutagenesis. 11:1996;213-215.
152. Landi S., Frenzilli G., Sbrana I., Barale R. Modulating factors of individual sensitivity to diepoxybutane: sister chromatid exchanges induced in vitro in human lymphocytes. Mutat. Res. 357:1996;75-82.
153. Wiencke J.K., Pemble S., Ketterer B., Kelsey K.T. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol. Biomarkers Prev. 4:1995;253-259.
154. Norppa H., Hirvonen A., Jarventaus H., Uuskula M., Tasa G., Ojajarvi A., Sorsa M. Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis. 16:1995;1261-1264.
155. Landi S., Ponzanelli I., Barale R. Effect of red cells and plasma blood in determining individual lymphocytes sensitivity to diepoxybutene assessed by in vitro induced sister chromatid exchanges. Mutat. Res. 348:1995;117-123.
156. Wiencke J.K., Christiani D.C., Kelsey K.T. Bimodal distribution of sensitivity to SCE induction by diepoxybutane in human lymphocytes. I. Correlation with chromosomal aberrations. Mutation Res. 248:1991;17-26.
157. Porfirio B., Dallapiccola B., Mokini V., Alimena G., Gandini E. Failure of diepoxybutane to enhance sister chromatid exchange levels in Fanconi's anemia patients and heterozygotes. Hum. Genet. 63:1983;117-120.
158. Wiencke J.K., Vosika J., Johnson P., Wang N., Garry V.F. Differential induction of sister chromatid exchange by chemical carcinogens in lymphocytes cultured from patients with solid tumors. Pharmacology. 24:1982;67-73.
159. Adler I.-D., Kliesch U., Tiveron C., Pacchierotti F. Clastogenicity of diepoxybutane in bone marrow cells and male germ cells of mice. Mutagenesis. 10:1995b;535-541.
160. Vlachodimitropoulos D., Norppa H., Autio K., Catalan J., Hirvonen A., Tasa G., Uuskula M., Demopoulos N.A., Sorsa M. GSTT1-dependent induction of centromere-negative and -positive micronuclei by 1,2:3,4-diepoxybutane in cultured human lymphocytes. Mutagenesis. 12:1997;397-403.
161. Marx M.P., Smith S., Heyns A.P., van Tonder I.Z. Fanconi's anemia: a cytogenetic study on lymphocyte and bone marrow cultures utilizing 1,2:3,4-diepoxybutane. Cancer Genet. Cytogenet. 9:1983;51-60.
162. Cohen M.M., Fruchtman C.E., Simpson S.J., Martin A.O. The cytogenetic response of Fanconi's anemia lymphoblastoid cell lines to various clastogens. Cytogenet. Cell Genet. 34:1982;230-240.
163. Auerbach A.D., Wolman S.R. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature. 261:1976;494-496.
164. Landi S., Norppa H., Frenzilli G., Cipollini G., Ponzanelli I., Barale R., Hirvonen A. Individual sensitivity to Cytogenetic effects of 1,2:3,4-diepoxybutane in cultured human lymphocytes: influence of glutathione S-transferase M1, P1 and T1 genotypes. Pharmacogenetics. 8:1998;461-471.
165. Pacchierotti F., Adler I.-D., Anderson D., Brinkworth M., Demopoulos N.A., Lahdetie J., Osterman-Golkar K.P., Russo A., Tates A., Waters R. Genetic effects of 1,3-butadiene and associated risk for heritable damage. Mutat. Res. 397:1998;93-115.
166. Sobels F.H. Approaches to assessing genetic risks from exposure to chemicals. Environ. Health Perspect. 101(Suppl. 3):1993;327-332.
167. Waters M.D., Nolan C. Meeting report of the EC/US workshop on genetic risk assessment: human genetic risks from exposure to chemicals, focusing on the feasibility of a parallelogram approach. Mutat. Res. 307:1994;411-424.
168. Recio L., Steen A.-M., Bond J.A. Linking dosimetry of butadiene with mutational spectra to assess the roles of epoxybutene and diepoxybutane in the genotoxicity of butadiene. CIIT Activities. 17(8):1997;1-10.
169. H. Ma, T.G. Wood, J.B. Ward, in Society of Toxicology 38th Annual Meeting, New Orleans, LA, Oxford University Press, Oxford, 1999, p. 126.
170. Saranko C.J., Pluta L.J., Recio L. Molecular analysis of lacI mutants from transgenic fibroblasts exposed to 1,2-epoxibutene. Carcinogenesis. 19:1998;1879-1887.
171. Saranko C.J., Recio L. The butadiene metabolite, 1,2:3,4-diepoxybutane, induces micronuclei but is only weakly mutagenic at lacI in the Big Blue rat2 lacI transgenic cell line. Environ. Mol. Mutagen. 31:1998;32-40.
172. Tretyakova N.Y., Sangaiah R., Yen T.-Y., Swenberg J.A. Synthesis, characterization, and in vitro quantitation of N-7-guanine adducts of diepoxybutane. Chem. Res. Toxicol. 10:1997;779-785.
173. Hasset C., Aicher L., Sidhu J.S., Omiecinski C.J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Human Mol. Genet. 3:1994;421-428.